BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BioCentury | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

Forma’s $100 million in series D financing will fuel the company's push to join the wave of progress in sickle cell disease and complete its transformation from a chemistry research organization to a therapeutics company...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Jan 4, 2019
Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

Suzhou Connect Biopharmaceuticals Ltd. (Taicang, China) raised $55 million on Jan. 2 in a series B round led by new investor Advantech Capital and announced plans to start a Phase Ib trial this quarter of...
BioCentury | Jan 3, 2019
Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

Suzhou Connect Biopharmaceuticals Ltd. (Taicang, China) raised $55 million in a series B round Wednesday led by new investor Advantech Capital and announced plans to start a Phase Ib trial this quarter of its second...
BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes...
BioCentury | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
BioCentury | May 14, 2018
Financial News

CellCentric raises $26M to advance into the clinic

CellCentric Ltd. (Little Chesterford, U.K.) said it has raised $26 million in an undisclosed private financing round from existing investor Morningside Venture Investments. Early this summer, CellCentric plans to begin Phase I testing of lead...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture and mouse studies identified a peptide-based inhibitor of the MYB-CREBBP interaction that could help treat AML. The inhibitor consisted of a retro-inverso form of a MYB...
Items per page:
1 - 10 of 73